MiNK Therapeutics, Inc.

MiNK Therapeutics is a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. The company's lead candidate, agenT-797, is an off-the-shelf native iNKT cell therapy currently in Phase 2 trials evaluating its combination with botensilimab, balstilimab, ramucirumab, and paclitaxel for previously treated advanced esophageal, gastric, and gastro-esophageal junction adenocarcinoma. agenT-797 is also being evaluated in Phase 1 trials as monotherapy combined with anti-PD-1 checkpoint inhibitors pembrolizumab and nivolumab for refractory solid tumors, and for treatment of moderate to severe viral acute respiratory distress syndrome.

The company's pipeline includes MiNK-215, an IL-15 armored tumor stromal-targeting FAP-CAR-iNKT program for solid tumors and inflammation, and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for autoimmune diseases. MiNK Therapeutics maintains collaborations with Autonomous Therapeutics and ImmunoScape, Inc. to advance its therapeutic approaches.

Based in New York, the company operates as a subsidiary of Agenus Inc. and employs 23 full-time staff members. The company was incorporated in Delaware in 2017 and was formerly known as AgenTus Therapeutics before rebranding in June 2021.